为研究中国气象局(China Meteorological Administration,CMA)研发的中国第一代全球再分析产品CRA(CMA Global Reanalysis)对海雾模拟的适用性,将CRA与欧洲中心再分析产品ERA5(the 5th Generation of ECMWF Reanalysis)以及美国国家环...为研究中国气象局(China Meteorological Administration,CMA)研发的中国第一代全球再分析产品CRA(CMA Global Reanalysis)对海雾模拟的适用性,将CRA与欧洲中心再分析产品ERA5(the 5th Generation of ECMWF Reanalysis)以及美国国家环境预报中心的再分析产品FNL(Final Reanalysis Data)分别作为WRF(Weather Research and Forecast)模式驱动的初边界条件,对发生在琼州海峡的一次持续性海雾过程进行数值模拟。结果表明:将3种再分析产品作为初始场均能模拟出琼州海峡海雾发展过程。CRA和ERA5模拟的海雾在偏东风下开始发展,风向转为东北风后消散。CRA模拟的海雾强度最强且维持时间最长,FNL模拟的底层风场较早转为东北风,海雾消散早。在垂直方向上,ERA5和CRA模拟的海雾发展高度与实况接近,FNL则明显偏低。CRA中较低的逆温层以及近地层温度将水汽聚集在低层,使得海雾可以持续发展并长时间维持。在加入实时更新的高分辨率海温后,模拟的气海温差场更精细,可反映出琼州海峡中部及东部气海温差小于0.5℃的区域,模拟海雾发展的能力更强。展开更多
目的探讨长链非编码RNA ABHD11-AS1对胃癌细胞糖酵解的影响及其作用的分子机制。方法分别将空载质粒pcDNA-Vector和过表达质粒pcDNA-ABHD11-AS1转染入ABHD11-AS1低表达的MKN45和MGC803胃癌细胞中,构建过表达组(pcDNA-ABHD11-AS1)和空载...目的探讨长链非编码RNA ABHD11-AS1对胃癌细胞糖酵解的影响及其作用的分子机制。方法分别将空载质粒pcDNA-Vector和过表达质粒pcDNA-ABHD11-AS1转染入ABHD11-AS1低表达的MKN45和MGC803胃癌细胞中,构建过表达组(pcDNA-ABHD11-AS1)和空载质粒对照组胃癌细胞株。运用CCK-8法检测细胞的增殖活性并绘制生长曲线,克隆形成实验检测细胞克隆形成能力,Transwell检测细胞迁移、侵袭能力,葡萄糖摄取实验及乳酸生成实验检测细胞糖酵解水平的变化;LncMAP数据库分析查找ABHD11-AS1可能调控的转录因子,查阅文献进行分析挑选候选转录因子,Western blot明确ABHD11-AS1是否影响候选转录因子的表达量。结果与对照组相比,转染pcDNA-ABHD11-AS1后,MGC803和MKN45胃癌细胞中ABHD11-AS1基因表达量明显上升(P<0.01),CCK8和成克隆实验表明细胞增殖加快(P<0.05),克隆形成能力增强,Tanswell实验结果证实细胞迁移(11±2 vs 27±3;17±4 vs 28±3,P<0.01)、侵袭(15±3 vs 26±2;10±1 vs 35±2,P<0.01)作用增强;上调ABHD11-AS1后,胃癌细胞葡萄糖摄取及乳酸生成增多(P<0.05)。分析数据库结果显示ABHD11-AS1可能调控经典糖酵解相关基因c-Myc,Western blot结果证实上调ABHD11-AS1后,c-Myc表达量随之升高。结论ABHD11-AS1通过上调c-Myc促进胃癌细胞内的糖酵解,并加速胃癌进展。展开更多
背景与目的:越来越多的多原发性早期肺癌患者选择接受立体定向放射治疗(stereotactic body radiation therapy,SBRT),本研究旨在回顾性分析SBRT的疗效及预后因素。方法:符合纳入标准的2014年8月—2020年12月于上海交通大学医学院附属胸...背景与目的:越来越多的多原发性早期肺癌患者选择接受立体定向放射治疗(stereotactic body radiation therapy,SBRT),本研究旨在回顾性分析SBRT的疗效及预后因素。方法:符合纳入标准的2014年8月—2020年12月于上海交通大学医学院附属胸科医院接受SBRT的241例患者进入本研究,对其中的多原发性早期肺癌患者进行疗效及预后因素分析,并采用倾向性评分匹配(propensity score matching,PSM)后,观察与单原发性早期肺癌SBRT效果的差异性。结果:241例接受SBRT的早期肺癌患者纳入本研究,其中多原发性早期肺癌94例,3和5年局部控制率(local control rate,LC)、无进展生存率(progression-free survival,PFS)和总生存率(overall survival,OS)分别为87.1%和71.3%、84.0%和66.9%、93.3%和79.3%。多原发性早期肺癌患者无3级以上肺炎毒性率,合计毒性率为54.3%,24例(25.5%)患者出现2级毒性。18例(19.1%)出现复发,其中多原发性早期肺癌患者出现局部复发、区域复发、远处转移及不确定性死亡分别为3例(3.2%)、1例(1.1%)、12例(12.7%)及2例(2.1%)。PSM前,多原发性早期肺癌患者与单原发性早期肺癌患者的临床特征存在显著差异。PSM后,多原发性早期肺癌患者和单原发性早期肺癌患者各有56例,在LC(P=0.291)、PFS(P=0.954)和OS(P=0.880)方面差异无统计学意义。94例多原发性早期肺癌患者的SBRT预后因素分析显示,年龄≥70岁是多原发性早期肺癌OS的独立危险因素。同时性和异时性多原发性早期肺癌两组间差异无统计学意义(P=0.440)。对于59例首-末次治疗间隔5年内的同时性多原发性早期肺癌患者,肿瘤病灶治疗总个数差异无统计学意义(P=0.232),多次治疗中不同治疗方法差异无统计学意义(P=0.225)。结论:多原发性早期肺癌SBRT效果较好,与单原发性早期肺癌的疗效相当,SBRT可能是多原发性早期肺癌一种良好的治疗选择。今后需要探讨多原发性早期肺癌基于年龄和肿瘤生物学行为的病灶局部干预策略和技术。展开更多
Background In China's Mainland,patients with neovascular age-related macular degeneration(nAMD)have approximately an 40%prevalence of polypoidal choroidal vasculopathy(PCV).This disease leads to recurrent retinal ...Background In China's Mainland,patients with neovascular age-related macular degeneration(nAMD)have approximately an 40%prevalence of polypoidal choroidal vasculopathy(PCV).This disease leads to recurrent retinal pigment epithelium detachment(PED),extensive subretinal or vitreous hemorrhages,and severe vision loss.China has introduced various treatment modalities in the past years and gained comprehensive experience in treating PCV.Methods A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes,regarding opinions on inactive PCV,choices of anti-vascular endothelial growth factor(anti-VEGF)monotherapy,photodynamic therapy(PDT)monotherapy or combined therapy,patients with persistent subretinal fluid(SRF)or intraretinal fluid(IRF)after loading dose anti-VEGF,and patients with massive subretinal hemorrhage.An evidence synthesis team conducted systematic reviews,which informed the recommendations that address these questions.This guideline used the GRADE(Grading of Recommendations,Assessment,Development,and Evaluation)approach to assess the certainty of evidence and grade the strengths of recommendations.Results The panel proposed the following six conditional recommendations regarding treatment choices.(1)For patients with inactive PCV,we suggest observation over treatment.(2)For treatment-na?ve PCV patients,we suggest either anti-VEGF monotherapy or combined anti-VEGF and PDT rather than PDT monotherapy.(3)For patients with PCV who plan to initiate combined anti-VEGF and PDT treatment,we suggest later/rescue PDT over initiate PDT.(4)For PCV patients who plan to initiate anti-VEGF monotherapy,we suggest the treat and extend(TE)regimen rather than the pro re nata(PRN)regimen following three monthly loading doses.(5)For patients with persistent SRF or IRF on optical coherence tomography(OCT)after three monthly anti-VEGF treatments,we suggest proceeding with anti-VEGF treatment rather than observation.(6)For PCV patients with massive subretinal hemorrhage(equal to or more than four optic disc areas)involving the central macula,we suggest surgery(vitrectomy in combination with tissue-plasminogen activator(tPA)intraocular injection and gas tamponade)rather than anti-VEGF monotherapy.Conclusions Six evidence-based recommendations support optimal care for PCV patients'management.展开更多
文摘为研究中国气象局(China Meteorological Administration,CMA)研发的中国第一代全球再分析产品CRA(CMA Global Reanalysis)对海雾模拟的适用性,将CRA与欧洲中心再分析产品ERA5(the 5th Generation of ECMWF Reanalysis)以及美国国家环境预报中心的再分析产品FNL(Final Reanalysis Data)分别作为WRF(Weather Research and Forecast)模式驱动的初边界条件,对发生在琼州海峡的一次持续性海雾过程进行数值模拟。结果表明:将3种再分析产品作为初始场均能模拟出琼州海峡海雾发展过程。CRA和ERA5模拟的海雾在偏东风下开始发展,风向转为东北风后消散。CRA模拟的海雾强度最强且维持时间最长,FNL模拟的底层风场较早转为东北风,海雾消散早。在垂直方向上,ERA5和CRA模拟的海雾发展高度与实况接近,FNL则明显偏低。CRA中较低的逆温层以及近地层温度将水汽聚集在低层,使得海雾可以持续发展并长时间维持。在加入实时更新的高分辨率海温后,模拟的气海温差场更精细,可反映出琼州海峡中部及东部气海温差小于0.5℃的区域,模拟海雾发展的能力更强。
文摘目的探讨长链非编码RNA ABHD11-AS1对胃癌细胞糖酵解的影响及其作用的分子机制。方法分别将空载质粒pcDNA-Vector和过表达质粒pcDNA-ABHD11-AS1转染入ABHD11-AS1低表达的MKN45和MGC803胃癌细胞中,构建过表达组(pcDNA-ABHD11-AS1)和空载质粒对照组胃癌细胞株。运用CCK-8法检测细胞的增殖活性并绘制生长曲线,克隆形成实验检测细胞克隆形成能力,Transwell检测细胞迁移、侵袭能力,葡萄糖摄取实验及乳酸生成实验检测细胞糖酵解水平的变化;LncMAP数据库分析查找ABHD11-AS1可能调控的转录因子,查阅文献进行分析挑选候选转录因子,Western blot明确ABHD11-AS1是否影响候选转录因子的表达量。结果与对照组相比,转染pcDNA-ABHD11-AS1后,MGC803和MKN45胃癌细胞中ABHD11-AS1基因表达量明显上升(P<0.01),CCK8和成克隆实验表明细胞增殖加快(P<0.05),克隆形成能力增强,Tanswell实验结果证实细胞迁移(11±2 vs 27±3;17±4 vs 28±3,P<0.01)、侵袭(15±3 vs 26±2;10±1 vs 35±2,P<0.01)作用增强;上调ABHD11-AS1后,胃癌细胞葡萄糖摄取及乳酸生成增多(P<0.05)。分析数据库结果显示ABHD11-AS1可能调控经典糖酵解相关基因c-Myc,Western blot结果证实上调ABHD11-AS1后,c-Myc表达量随之升高。结论ABHD11-AS1通过上调c-Myc促进胃癌细胞内的糖酵解,并加速胃癌进展。
文摘背景与目的:越来越多的多原发性早期肺癌患者选择接受立体定向放射治疗(stereotactic body radiation therapy,SBRT),本研究旨在回顾性分析SBRT的疗效及预后因素。方法:符合纳入标准的2014年8月—2020年12月于上海交通大学医学院附属胸科医院接受SBRT的241例患者进入本研究,对其中的多原发性早期肺癌患者进行疗效及预后因素分析,并采用倾向性评分匹配(propensity score matching,PSM)后,观察与单原发性早期肺癌SBRT效果的差异性。结果:241例接受SBRT的早期肺癌患者纳入本研究,其中多原发性早期肺癌94例,3和5年局部控制率(local control rate,LC)、无进展生存率(progression-free survival,PFS)和总生存率(overall survival,OS)分别为87.1%和71.3%、84.0%和66.9%、93.3%和79.3%。多原发性早期肺癌患者无3级以上肺炎毒性率,合计毒性率为54.3%,24例(25.5%)患者出现2级毒性。18例(19.1%)出现复发,其中多原发性早期肺癌患者出现局部复发、区域复发、远处转移及不确定性死亡分别为3例(3.2%)、1例(1.1%)、12例(12.7%)及2例(2.1%)。PSM前,多原发性早期肺癌患者与单原发性早期肺癌患者的临床特征存在显著差异。PSM后,多原发性早期肺癌患者和单原发性早期肺癌患者各有56例,在LC(P=0.291)、PFS(P=0.954)和OS(P=0.880)方面差异无统计学意义。94例多原发性早期肺癌患者的SBRT预后因素分析显示,年龄≥70岁是多原发性早期肺癌OS的独立危险因素。同时性和异时性多原发性早期肺癌两组间差异无统计学意义(P=0.440)。对于59例首-末次治疗间隔5年内的同时性多原发性早期肺癌患者,肿瘤病灶治疗总个数差异无统计学意义(P=0.232),多次治疗中不同治疗方法差异无统计学意义(P=0.225)。结论:多原发性早期肺癌SBRT效果较好,与单原发性早期肺癌的疗效相当,SBRT可能是多原发性早期肺癌一种良好的治疗选择。今后需要探讨多原发性早期肺癌基于年龄和肿瘤生物学行为的病灶局部干预策略和技术。
文摘Background In China's Mainland,patients with neovascular age-related macular degeneration(nAMD)have approximately an 40%prevalence of polypoidal choroidal vasculopathy(PCV).This disease leads to recurrent retinal pigment epithelium detachment(PED),extensive subretinal or vitreous hemorrhages,and severe vision loss.China has introduced various treatment modalities in the past years and gained comprehensive experience in treating PCV.Methods A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes,regarding opinions on inactive PCV,choices of anti-vascular endothelial growth factor(anti-VEGF)monotherapy,photodynamic therapy(PDT)monotherapy or combined therapy,patients with persistent subretinal fluid(SRF)or intraretinal fluid(IRF)after loading dose anti-VEGF,and patients with massive subretinal hemorrhage.An evidence synthesis team conducted systematic reviews,which informed the recommendations that address these questions.This guideline used the GRADE(Grading of Recommendations,Assessment,Development,and Evaluation)approach to assess the certainty of evidence and grade the strengths of recommendations.Results The panel proposed the following six conditional recommendations regarding treatment choices.(1)For patients with inactive PCV,we suggest observation over treatment.(2)For treatment-na?ve PCV patients,we suggest either anti-VEGF monotherapy or combined anti-VEGF and PDT rather than PDT monotherapy.(3)For patients with PCV who plan to initiate combined anti-VEGF and PDT treatment,we suggest later/rescue PDT over initiate PDT.(4)For PCV patients who plan to initiate anti-VEGF monotherapy,we suggest the treat and extend(TE)regimen rather than the pro re nata(PRN)regimen following three monthly loading doses.(5)For patients with persistent SRF or IRF on optical coherence tomography(OCT)after three monthly anti-VEGF treatments,we suggest proceeding with anti-VEGF treatment rather than observation.(6)For PCV patients with massive subretinal hemorrhage(equal to or more than four optic disc areas)involving the central macula,we suggest surgery(vitrectomy in combination with tissue-plasminogen activator(tPA)intraocular injection and gas tamponade)rather than anti-VEGF monotherapy.Conclusions Six evidence-based recommendations support optimal care for PCV patients'management.